Nina Shah, MD

Nina Shah, MD, an associate professor of Medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the potential role of idecabtagene vicleucel (ide-cel; BB2121) as treatment of patients with multiple myeloma.

Ide-cel is a a BCMA-directed chimeric antigen receptor (CAR) T-cell therapy. The original data from the phase 2 KarMMA study (NCT03361748) demonstrated a 73% overall response rate, and the rate was even higher in the 450 dose, which will be the dose moving forward. The progression-free survival was approximately 1 year, so physicians know this therapy works, especially in this heavily pretreated patient population.

Videos

Nina Shah, MD, discusses the potential role of idecabtagene vicleucel as treatment of patients with multiple myeloma.

Ide-Cel CAR T-Cell Therapy Demonstrates Promise in Heavily Pretreated Myeloma

Nina Shah, MD, an associate professor of Medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the question of whether chimeric antigen receptor (CAR) T-cell therapy is ready for primetime in patients with multiple myeloma.

Shah says it is not primetime for CAR T cells in multiple myeloma yet, but the reason for asking this question is because of the significant responses that have been demonstrated with CAR T cells already in this space. The therapy induced response rates around 85% to 90% in patients who are heavily pretreated with multiple myeloma, where the median number of prior lines is 7. These kind of response rates are unheard of in this patient population, Shah says, and CAR T-cell therapy is ultimately rescuing a lot of really sick patients.

Nina Shah, MD, discusses the question of whether CAR T-cell therapy is ready for primetime in patients with multiple myeloma.

Nina Shah, MD | Authors

Articles

Ide-Cel CAR T-Cell Therapy Demonstrates Promise in Heavily Pretreated Myeloma

Shah Discusses Hope for CAR T-Cell Therapy in Multiple Myeloma